Journal Mobile Options
Table of Contents
Vol. 65, No. 2, 2003
Issue release date: August 2003

Expression of Phosphatidylethanolamine N-Methyltransferase in Human Hepatocellular Carcinomas

Tessitore L. · Marengo B. · Vance D.E. · Papotti M. · Mussa A. · Daidone M.G. · Costa A.
To view the fulltext, log in and/or choose pay-per-view option

Individual Users: Register with Karger Login Information

Please create your User ID & Password





Contact Information











I have read the Karger Terms and Conditions and agree.

To view the fulltext, please log in

To view the pdf, please log in

Abstract

Objective: Hepatic phosphatidylethanolamine is converted into phosphatidylcholine by the enzyme phosphatidylethanolamine N-methyltransferase (PEMT) when the dietary choline supply is inadequate. Our previous reports implicated PEMT in the regulation of hepatocyte growth and transformation. In the present study, we analyzed PEMT activity, Pempt gene status and its mRNA expression in 29 human hepatocellular carcinomas (HCC). Methods: The status of the Pempt gene and PEMT2 mRNA expression were evaluated with Southern and Northern blotting, respectively, in HCC and the noninvolved liver. PEMT activity was assessed by biochemical assay. Cell proliferation markers were defined by immunohistochemical or histoautoradiographic methods. Results: PEMT activity was lower in HCC than in the noninvolved liver and it was negligible in 62% of the tumors. No deletions or mutations of the Pempt gene were found and PEMT2 mRNA expression was absent or reduced in HCC compared with peritumoral liver tissue. PEMT2 mRNA expression was inversely related to tumor proliferation and to histologic grade. Patients whose HCC did not express PEMT2 mRNA showed poorer outcomes for cancer-related survival than those with PEMT2-positive HCC. Conclusions: The present findings suggest that (1) clones lacking PEMT2 expression may have been selected during liver tumorigenesis and progression, and (2) PEMT2 expression seems to be associated with clinical progression.



Copyright / Drug Dosage

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

References

  1. Walkey CJ, Yu L, Agellon LB, Vance DE: Biochemical and evolutionary significance of phospholipid methylation. J Biol Chem 1998;273:27043–27046.
  2. Cui Z, Vance JE, Chen MH, Voelker DR, Vance DE: Cloning and expression of a novel phosphatidylethanolamine N-methyltransferase. A specific biochemical and cytological marker for a unique membrane fraction in rat liver. J Biol Chem 1993;268:16655–16663.
  3. Tessitore L, Cui Z, Vance DE: Transient inactivation of phosphatidylethanolamine N-methyltransferase-2 and activation of cytidine triphosphate: Phosphocholine cytidylyl-transferase during non-neoplastic liver growth. Biochem J 1997;322:151–154.
  4. Houweling M, Cui Z, Tessitore L, Vance DE: Induction of hepatocyte proliferation after partial hepatectomy is accompanied by a markedly reduced expression of phosphatidylethanolamine N-methyltransferase. Biochim Biophys Acta 1997;1346:1–9.
  5. Tessitore L, Dianzani I, Cui Z, Vance DE: Diminished expression of phosphatidylethanolamine N-methyltransferase-2 during hepatocarcinogenesis. Biochem J 1999;337:23–27.
  6. Tessitore L, Sesca E, Vance DE: Inactivation of phosphatidylethanolamine N-methyltransferase-2 in aflatoxin-induced liver cancer and partial reversion of the neoplastic phenotype by PEMT transfection of hepatoma cells. Int J Cancer 2000;86:362–367.
  7. Tessitore L, Sesca E, Bosco M, Vance DE: Expression of phosphatidylethanolamine N-methyltransferase in Yoshida ascites hepatoma cells and the liver of host rats. Carcinogenesis 1999;20:561–567.
  8. Cui Z, Houweling M, Vance DE: Suppression of rat hepatoma cell growth by expression of phosphatidylethanolamine N-methyltransferase-2. J Biol Chem 1994;269:24531–24533.
  9. Cui Z, Houweling M, Vance DE: Expression of phosphatidylethanolamine N-methyltransferase-2 in McArdle-RH7777 hepatoma cells inhibits the CDP-choline pathway for phosphatidylcholine biosynthesis via decreased gene expression of CTP: Phosphocholine cytidylyl transferase. Biochem J 1995;312:939–945.
  10. Edmondson HA, Steiner PE: Primary carcinoma of the liver. A study of 100 cases among 48,900 necropsies. Cancer 1954;7:462–503.
  11. Sambrook J, Fritsch EF, Maniatis TE: Molecular Cloning, a Laboratory Manual. Cold Spring Harbor, Cold Spring Harbor Laboratory Press, 1989.
  12. Walkey CJ, Shields DJ, Vance DE: Identification of three novel cDNA for human phosphatidylethanolamine N-methyltransferase and localization of the human gene on chromosome 17p11.2. Biochim Biophys Acta 1999;1436:405–412.
  13. Chomuzynski P, Sacchi M: Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem 1987;162:156–159.
  14. Ridgway ND, Vance DE: Phosphatidylethanolamine N-methyltransferase from rat liver. Methods Enzymol 1992;209:366–374.
  15. Vance DE, Pelech SD, Choy PC: CTP-phosphocholine cytidylyltransferase from rat liver. Methods Enzymol 1981;71:576–581.
  16. Silvestrini R, Daidone MG, Costa A: Determination of the cell proliferative fraction in human tumours; in Studzinski GP (ed): Cell Growth and Apoptosis. A Practical Approach. New York, Oxford University Press, 1995, pp 59–77.
  17. Silvestrini R, the SICCAB Group for Quality Control of Cell Kinetic Determination: Feasibility and reproducibility of the 3H-thymidine labelling index in breast cancer. Cell Prolif 1991;21:437–445.
  18. Silvestrini R, Costa A, Gennari L, Doci R, Bombardieri E, Bombelli L: Cell kinetics of hepatic metastases as a prognostic marker in patients with advanced colorectal carcinoma. HPB Surg 1990;2:135–144.
  19. Sesca E, Perletti GP, Binasco V, Chiara M, Tessitore L: Phosphatidylethanolamine N-methyltransferase-2 and CTP-phosphocholine cytidylyl transferase expressions are related with protein kinase C isozymes in developmental liver growth. Biochem Biophys Res Commun 1996;229:158–162.
  20. Ito Y, Matsuura N, Sakon M, Miyoshi E, Noda K, Takeda T, Umeshita K, Nagano H, Nakamori S, Dono K, Tsujimoto M, Nakahara M, Nakao K, Taniguchi N, Monden M: Expression and prognostic roles of the G1-S modulators in hepatocellular carcinoma: p27 independently predicts the recurrence. Hepatology 1999;30:90–99.
  21. Walkey CJ, Donohue LR, Bronson R, Agellon LB, Vance DE: Disruption of the murine gene encoding phosphatidylethanolamine N-methyltransferase. Proc Natl Acad Sci USA 1997;94:12880–12886.


Pay-per-View Options
Direct payment This item at the regular price: USD 38.00
Payment from account With a Karger Pay-per-View account (down payment USD 150) you profit from a special rate for this and other single items.
This item at the discounted price: USD 26.50